BR0112375A - Métodos de sìntese para aplidina e novos derivados antitumorais, métodos para fabrica-los e usá-los. - Google Patents

Métodos de sìntese para aplidina e novos derivados antitumorais, métodos para fabrica-los e usá-los.

Info

Publication number
BR0112375A
BR0112375A BR0112375-0A BR0112375A BR0112375A BR 0112375 A BR0112375 A BR 0112375A BR 0112375 A BR0112375 A BR 0112375A BR 0112375 A BR0112375 A BR 0112375A
Authority
BR
Brazil
Prior art keywords
methods
aplidine
making
new antitumor
derivatives
Prior art date
Application number
BR0112375-0A
Other languages
English (en)
Other versions
BRPI0112375B8 (pt
BRPI0112375B1 (pt
Inventor
Ignacio Rodrigues
Concepcion Polanco
Felix Cuevas
Paloma Mandez
Carmen Cuevas
Pilar Gallego
Simon Munt
Ignacio Manzanares
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0016148A external-priority patent/GB0016148D0/en
Priority claimed from GB0103750A external-priority patent/GB0103750D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR0112375A publication Critical patent/BR0112375A/pt
Publication of BRPI0112375B1 publication Critical patent/BRPI0112375B1/pt
Publication of BRPI0112375B8 publication Critical patent/BRPI0112375B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

"MéTODOS DE SìNTESE PARA APLIDINA E NOVOS DERIVADOS ANTITUMORAIS, MéTODOS PARA FABRICá-LOS E USá-LOS". A invenção fornece derivados de aplidina e métodos de síntese.
BR0112375A 2000-06-30 2001-07-02 aplidinas como derivados antitumorais BRPI0112375B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0016148.9 2000-06-30
GB0016148A GB0016148D0 (en) 2000-06-30 2000-06-30 Synthetic methods for aplidine and new antitiumoral derivatives
GB0103750A GB0103750D0 (en) 2001-02-15 2001-02-15 Synthetic methods for aplidine and new antitumoral derivatives methods of making and using them
GB0103750.6 2001-02-15
PCT/GB2001/002901 WO2002002596A2 (en) 2000-06-30 2001-07-02 Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them

Publications (3)

Publication Number Publication Date
BR0112375A true BR0112375A (pt) 2003-06-24
BRPI0112375B1 BRPI0112375B1 (pt) 2020-12-01
BRPI0112375B8 BRPI0112375B8 (pt) 2021-05-25

Family

ID=26244577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112375A BRPI0112375B8 (pt) 2000-06-30 2001-07-02 aplidinas como derivados antitumorais

Country Status (25)

Country Link
US (2) US7348310B2 (pt)
EP (1) EP1294747B1 (pt)
JP (1) JP5289662B2 (pt)
KR (1) KR100866056B1 (pt)
CN (2) CN104650177A (pt)
AT (1) ATE393775T1 (pt)
AU (1) AU6769801A (pt)
BR (1) BRPI0112375B8 (pt)
CA (1) CA2414609C (pt)
CY (1) CY1108549T1 (pt)
CZ (1) CZ304204B6 (pt)
DE (1) DE60133817T2 (pt)
DK (1) DK1294747T3 (pt)
ES (1) ES2305083T3 (pt)
HK (1) HK1052940B (pt)
HU (1) HU228998B1 (pt)
IL (2) IL153680A0 (pt)
MX (1) MXPA03000202A (pt)
NO (1) NO334096B1 (pt)
NZ (1) NZ523367A (pt)
PL (1) PL208651B1 (pt)
PT (1) PT1294747E (pt)
SI (1) SI1294747T1 (pt)
UA (1) UA76718C2 (pt)
WO (1) WO2002002596A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
SI1229922T1 (sl) * 1999-11-15 2008-04-30 Pharma Mar Sa Zdravljenje raka z aplidinom
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
AU2001251498A1 (en) 2000-04-07 2001-10-23 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US7507766B2 (en) 2000-10-12 2009-03-24 Pharma Mar, S.A. Treatment of cancers
RU2341283C2 (ru) 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
DE602004016126D1 (de) 2003-03-12 2008-10-09 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
MXPA05010064A (es) 2003-03-21 2006-05-17 Madeleine M Joullie Analogos de tamandarin y fragmentos de los mismos y metodos para hacerlos y usarlos.
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
CA2703024A1 (en) * 2007-10-19 2009-04-23 Giuseppe Longo Sorbello Improved antitumoral treatments
RU2010140888A (ru) * 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) Улучшенные противораковые терапии
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
JP2013537181A (ja) * 2010-09-10 2013-09-30 サノフイ 抗血栓活性及び改善された代謝安定性を有するビオチン化多糖類
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2021175826A1 (en) 2020-03-02 2021-09-10 Pharma Mar, S.A. Compounds for use in the treatment of coronavirus infection
JP2023517194A (ja) 2020-03-02 2023-04-24 ファルマ、マール、ソシエダード、アノニマ コロナウイルス感染の処置における組合せに使用するためのｐｌｄ
US20230158104A1 (en) 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in autoimmune conditions
MX2022010921A (es) 2020-03-02 2022-09-29 Pharma Mar Sa Compuestos para su uso en afecciones inflamatorias.
CN115594739A (zh) * 2021-06-28 2023-01-13 浙江珲达生物科技有限公司（Cn） 一种dehydrodidemnin B类化合物的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) * 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6509316B2 (en) * 1995-03-07 2003-01-21 George Washington University Pharmaceutical compositions, methods, and kits for treatment and diagnosis of lung cancer
ES2102322B1 (es) * 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
CA2269881A1 (en) * 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Semi-synthetic studies toward didemnin analogues
ATE245435T1 (de) * 1996-10-24 2003-08-15 Univ Illinois Totalsynthese des amino hip analogen von didemnin a
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
ES2321462T3 (es) * 1997-05-07 2009-06-05 Pharma Mar, S.A. Uso de aplidina para el tratamiento de enfermedades cardiovasculares.
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
AU764807B2 (en) 1998-07-30 2003-08-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CA2373643A1 (en) 1999-05-25 2000-11-30 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
SI1229922T1 (sl) 1999-11-15 2008-04-30 Pharma Mar Sa Zdravljenje raka z aplidinom
AU2001251498A1 (en) * 2000-04-07 2001-10-23 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
MXPA03003230A (es) 2000-10-12 2004-12-03 Pharma Mar Sa Tratamiento de canceres.
EP1435991B1 (en) 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
RU2341283C2 (ru) 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей

Also Published As

Publication number Publication date
BRPI0112375B8 (pt) 2021-05-25
US7348310B2 (en) 2008-03-25
CZ304204B6 (cs) 2014-01-02
HUP0301387A3 (en) 2005-04-28
PL208651B1 (pl) 2011-05-31
CN104650177A (zh) 2015-05-27
MXPA03000202A (es) 2003-10-15
DE60133817D1 (de) 2008-06-12
EP1294747A2 (en) 2003-03-26
JP5289662B2 (ja) 2013-09-11
BRPI0112375B1 (pt) 2020-12-01
WO2002002596A3 (en) 2002-05-23
WO2002002596A2 (en) 2002-01-10
HK1052940A1 (en) 2003-10-03
JP2004502702A (ja) 2004-01-29
US20080009435A1 (en) 2008-01-10
NO334096B1 (no) 2013-12-09
NO20026242L (no) 2003-02-27
NZ523367A (en) 2004-12-24
PL360531A1 (en) 2004-09-06
KR20030013477A (ko) 2003-02-14
DE60133817T2 (de) 2009-05-20
CY1108549T1 (el) 2014-04-09
CZ20024233A3 (cs) 2003-06-18
KR100866056B1 (ko) 2008-10-30
SI1294747T1 (sl) 2008-12-31
DK1294747T3 (da) 2008-10-27
HK1052940B (zh) 2008-10-24
CA2414609A1 (en) 2002-01-10
UA76718C2 (uk) 2006-09-15
ATE393775T1 (de) 2008-05-15
NO20026242D0 (no) 2002-12-27
US7678765B2 (en) 2010-03-16
US20040097413A1 (en) 2004-05-20
HUP0301387A2 (hu) 2003-08-28
HU228998B1 (en) 2013-07-29
ES2305083T3 (es) 2008-11-01
CN1449408A (zh) 2003-10-15
PT1294747E (pt) 2008-08-08
CA2414609C (en) 2012-04-24
AU6769801A (en) 2002-01-14
IL153680A0 (en) 2003-07-06
EP1294747B1 (en) 2008-04-30
IL153680A (en) 2012-05-31

Similar Documents

Publication Publication Date Title
BR0112375A (pt) Métodos de sìntese para aplidina e novos derivados antitumorais, métodos para fabrica-los e usá-los.
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
EG23400A (en) Database.
BR0216099B1 (pt) "conjunto de desgaste".
HK1055955A1 (en) Methanesulphonamido-benzofuran, preparation methodand use thereof as synthesis intermediate.
NO20040540L (no) 4-amino-6-fenylpyrrolo[2,3-D]pyrimidinderivater.
MXPA03004947A (es) Derivados de tetralona como agentes antitumorales.
BR0209242A (pt) Aminopolidiorganossiloxanos amido-funcionais
GB0104176D0 (en) Asymmetric dendrimers
MXPA02006130A (es) Tela de formacion para fabricantes de papel.
DE50310977D1 (de) Kompaktiertes menthol
AU2001233703A1 (en) Diethyloctandioldicarbamates and diethyloctandioldiallophanates, method for the production and use thereof
AU1817902A (en) Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
IT1317722B1 (it) Procedimento per la produzione di gas di sintesi.
IT1304443B1 (it) Dispositivo formatore di gruppi di sigarette.
DE69906149D1 (de) 4,5-azolo-oxindole
UY26574A1 (es) " procedimiento para la separación enzimática de racematos de derivados de aminometil-aril-ciclohexanol".
ID27733A (id) Metoksiminofenilasetamida
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
MXPA03007550A (es) Derivados coloporosidos, proceso para su preparacion y su uso.
AR027751A1 (es) Proceso para la n-formilacion selectiva de n-hidroxilaminas
ATE405668T1 (de) Exopolysaccharidproduktion
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
CY1115144T1 (el) Παραγωγα του uk-2a
BR0109394A (pt) Compostos de esponja antitumores

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 870180000107, APRESENTADA EM 02/01/2018, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA POIS NAO FOI PETICIONADA DENTRO DO PRAZO DE 29/10/2017 (QUE POR SER DOMINGO POSTERGA PARA 30/10/2017) DE ACORDO COM O 1O DO ART. 2O DA INSTRUCAO NORMATIVA INPI/DIRPA NO 03 DE 30/09/2016 E ART. 36 DA LEI 9.279 DE 14/05/1996. A PARTIR DESTA DATA CORRE PRAZO DE 60 DIAS PARA EVENTUAL RECURSO DO INTERESSADO.

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: O REQUERENTE APRESENTOU QUADRO REIVINDICATORIO COM 75 REIVINDICACOES CONFORME PETICAO 042267/RJ (ATUAL 060030042267) DE 31/07/2003. ATRAVES DA PETICAO 036469/RJ (ATUAL 060040036469) DE 29/06/2004 FOI PAGO O PEDIDO DE EXAME EQUIVALENTE A 10 REIVINDICACOES, COM O VALOR PAGO DE R$ 400,00 (QUATROCENTOS REAIS). NA RPI 2443 DE 31/10/2017 FOI FEITA A EXIGENCIA 6.7 DE COMPLEMENTACAO DO PEDIDO DE EXAME PARA REIVINDICACOES EXCEDENTES, CONFORME TABELA VIGENTE. A MESMA FOI RESPONDIDA UTILIZANDO A PETICAO 870180000107 DE 02/01/2018, QUE APRESENTOU A GRU 29409201712153040 NO VALOR DE R$ 2.900,00 (DOIS MIL E NOVECENTOS REAIS). FOI FEITO A ASSOCIACAO DA GRU AO PROTOCOLO DO PEDIDO DE EXAME. PELA TABELA ATUAL

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: O PI0112375-0 E UM PEDIDO FLUXO NOVO DA ANVISA, OU SEJA, ESTE PEDIDO AINDA NAO FOI EXAMINADO PELO INPI. A ANUENCIA DA ANVISA FOI DADA APOS ANALISE DE CRITERIOS DE PATENTEABILIDADE, O QUE SIGNIFICA APRESENTACAO DE SUBSIDIOS (CONFORME INSTRUCAO NORMATIVA INPI/DIRPA/CGREC NO 01 DE 31/05/2017). DESTA FORMA, APESAR DE O REQUERENTE TER AJUSTADO O QUADRO REIVINDICATORIO PARA 17 REIVINDICACOES DE ACORDO COM O EXAME ELABORADO PELA ANVISA E APRESENTADO ESTE MESMO QUADRO REIVINDICATORIO AO INPI, O QUADRO VALIDO E O DE 75 REIVINDICACOES, O EXAMINADOR PODE OU NAO ESTAR DE ACORDO COM O NOVO QUADRO REIVINDICATORIO TENDO EM VISTA QUE O EXAME FEITO PELA ANVISA TEM CARATER DE SUBSIDIOS AO EXAME TECNICO. DESTA

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: O REQUERENTE APRESENTOU QUADRO REIVINDICATORIO COM 75 REIVINDICACOES CONFORME PETICAO042267/RJ (ATUAL 060030042267) DE 31/07/2003. ATRAVES DA PETICAO 036469/RJ (ATUAL 060040036469) DE 29/06/2004 FOI PAGO O PEDIDO DE EXAME EQUIVALENTE A 10 REIVINDICACOES, COMO VALOR PAGO DE R$ 400,00 (QUATROCENTOS REAIS). NA PETICAO 870180000107 DE 02/01/2018, APRESENTOU A GRU 29409201712153040 NO VALOR DE R$ 2.900,00 (DOIS MIL E NOVECENTOS REAIS). NA PETICAO 870200068062 DE 01/06/2020, APRESENTOU A GRU 29409201919573668 NO VALOR DE R$ 23.100,00 (VINTE E TRES MIL E CEM REAIS). O SOMATORIO DOS VALORES PAGOS NO PEDIDO DE EXAME E COMPLEMENTACOES FOI DE R$ 26.400,00 (VINTE E SEIS MIL E QUATROCENTOS REAIS). DE A

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/07/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2677 DE 26-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.